Norlase
Latest round
- Series B
Last raised
- Oct 2021
Total raised
- $11M
Investors
- 1
About Norlase
Norlase ApS develops innovative ophthalmic laser technologies, enhancing the efficiency and portability of eye care treatments.Norlase ApS specializes in ophthalmic laser technology, founded in 2024 in Ballerup, Denmark. The company has not publicly disclosed any significant pivots or changes in business operations.Norlase specializes in the development and manufacturing of advanced ophthalmic laser technologies designed to enhance the efficiency and portability of eye care treatments. Their primary product offerings include the LYNX, ECHO, LION, and LEAF systems, each contributing unique capabilities to the field of ophthalmology. The LYNX is a pioneering laser indirect ophthalmoscope that introduces pattern scanning capabilities without the need for external consoles, enabling treatments in diverse settings. ECHO incorporates MEMS pattern technology into a compact laser engine, prioritizing portability and ease of use, while LION integrates a battery-powered green laser with a wireless interface for direct ophthalmoscopy. LEAF stands out as a green laser photocoagulator that attaches directly to existing slit lamps, optimizing space and functionality.Norlase's revenue model is built on the direct sale of its innovative laser systems to medical facilities, primarily ophthalmology practices, through a B2B transaction structure. The company leverages partnerships with distributors to reach a broader client base, ensuring that its technologically advanced products are accessible to eye care professionals. Each flagship product, such as the LION and ECHO, is positioned as a premium offering, with pricing strategies reflecting the advanced capabilities and integrated technologies these systems provide.Norlase ApS plans to launch new products that enhance their existing portfolio, focusing on advanced laser systems tailored for specific ophthalmic applications. The company aims to expand its market presence in regions like Asia and South America by 2026, responding to increased global demand.
Who invested in Norlase
1 investor across 1 round
See all investors in Norlase
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series B
Oct 25, 2021
Amount
$11M
Investors
Questions about Norlase
Who invested in Norlase?
Norlase has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Norlase raised?
Norlase has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Norlase last raise money?
Norlase's most recent round on record is a Series B, in Oct 2021.
What does Norlase do?
Norlase ApS develops innovative ophthalmic laser technologies, enhancing the efficiency and portability of eye care treatments.
Where is Norlase headquartered?
Norlase is headquartered in Ballerup, Denmark.
Which VCs invest in companies like Norlase?
Among active investors with capital left to deploy, Index Ventures, Forbion, Balderton Capital and Sofinnova Partners back healthcare companies at Norlase's stage. Their profiles are linked below.
VCs backing healthcare startups at Series B
Raising like Norlase? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.